Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors

References

• Zhao Y, Yu H, Hu W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim. Biophys. Sin. 46(3), 180–189 (2014).
   Google Scholar
• Nakamura H, Arai Y, Totoki Y et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47(9), 1003–1010 (2015).
   PubMed Web of Science ®Google Scholar
• Bouattour M, Valle JW, Vogel A et al. Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. J. Clin. Oncol. 41(Suppl. 4), 531 (2023).
   Google Scholar
• AACR Project Genie Consortium. AACR Project GENIE: powering precision medicine through an international consortium. J. Cancer Discov. 7(8), 818–831 (2017).
   PubMed Web of Science ®Google Scholar
• Cancer.Net. Gallbladder cancer: statistics. www.cancer.net/cancer-types/gallbladder-cancer/statistics (21st May, 2023).
   Google Scholar
• Ghidini M, Pizzo C, Botticelli A et al. Biliary tract cancer: current challenges and future prospects. Cancer Manag. Res. 11, 379–388 (2019).
   PubMed Web of Science ®Google Scholar
• Vogel A, Bridgewater J, Edeline J et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34(2), 127–140 (2023).
   PubMed Web of Science ®Google Scholar
• Oh D-Y, Ruth He A, Qin S et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. N. Eng. J. Med. Evid. 1(8), EVIDoa2200015 (2022).
   Google Scholar
• Kelley RK, Ueno M, Yoo C et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 401(10391), 1853–1865 (2023).
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J. Hepatol. 73(1), 170–185 (2020).
   PubMed Web of Science ®Google Scholar
• Karasic TB, Eads JR, Goyal L. Precision medicine and immunotherapy have arrived for cholangiocarcinoma: an overview of recent approvals and ongoing clinical trials. JCO Precis. Oncol. 7, e2200573 (2023).
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a Phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22(5), 690–701 (2021).
   PubMed Web of Science ®Google Scholar
• Yoo C, Kim K-P, Jeong JH et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, Phase 2b study. Lancet Oncol. 22(11), 1560–1572 (2021).
   PubMed Web of Science ®Google Scholar
• Cancer.Net. Pancreatic cancer: statistics. www.cancer.net/cancer-types/pancreatic-cancer/statistics#:∼:text=How%20many%20people%20are%20diagnosed,approximately%203%25%20of%20all%20cancers (21 May 2023).
   Google Scholar
• Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front. Oncol. 11, 688377 (2021).
   PubMed Web of Science ®Google Scholar
• Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J. Gastrointest. Oncol. 12(2), 173–181 (2020).
   PubMed Web of Science ®Google Scholar
• Hayuka K, Okuyama H, Murakami A et al. Gemcitabine plus nab-paclitaxel as second-line chemotherapy following FOLFIRINOX in patients with unresectable pancreatic cancer: a single-institution, retrospective analysis. Chemotherapy 66(3), 58–64 (2021).
   PubMed Web of Science ®Google Scholar
• Portal A, Pernot S, Tougeron D et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Brit. J. Cancer 113(7), 989–995 (2015).
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase 3 trial. Lancet 387(10018), 545–557 (2016).
   PubMed Web of Science ®Google Scholar
• Tempero MA. NCCN guidelines updates: pancreatic cancer. J. Natl Compr. Canc. Netw. 17(5.5), 603–605 (2019).
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M et al. Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 19(4), 439–457 (2021).
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255–265 (2017).
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised Phase 3 trial. Lancet 384(9944), 665–673 (2014).
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Eng. J. Med. 373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Powles T, Rosenberg JE, Sonpavde GP et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Eng. J. Med. 384(12), 1125–1135 (2021).
   PubMed Web of Science ®Google Scholar
• Rudolph D, Weyer-Czernilofsky U, Reschke M et al. BI-907828: a novel, and potent MDM2-p53 antagonist, acts synergistically in a triple combination with anti-PD-1 and anti-LAG-3 antibodies in syngeneic mouse models of cancer. Cancer Res. 79(Suppl. 3), 3197 (2019).
   Google Scholar
• LoRusso P, Yamamoto N, Patel MR et al. The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a Phase Ia, first-in-human, dose-escalation study. Cancer Discov. 13(8), 1802–1813 (2023).
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Tolcher AW, Hafez N et al. Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two Phase Ia/Ib dose-escalation/expansion trials. J. Clin. Oncol. 41(Suppl. 4), 543 (2023).
   Google Scholar